-
Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020
- Danuta M Skowronski1,2 , Macy Zou1 , Suzana Sabaiduc1 , Michelle Murti3,4 , Romy Olsha3 , James A Dickinson5 , Jonathan B Gubbay3,4 , Matthew A Croxen6,7 , Hugues Charest8 , Agatha Jassem1,2 , Mel Krajden1,2 , Nathalie Bastien9 , Yan Li9 , Gaston De Serres8,10,11
-
View Affiliations Hide AffiliationsAffiliations: 1 British Columbia Centre for Disease Control, Vancouver, Canada 2 University of British Columbia, Vancouver, Canada 3 Public Health Ontario, Toronto, Canada 4 University of Toronto, Toronto, Canada 5 University of Calgary, Calgary, Canada 6 Public Health Laboratory (ProvLab), Alberta Precision Laboratories, Edmonton, Alberta, Canada 7 University of Alberta, Edmonton, Canada 8 Institut National de Santé Publique du Québec, Québec, Canada 9 National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada 10 Laval University, Quebec, Canada 11 Centre Hospitalier Universitaire de Québec, Québec, CanadaDanuta M Skowronskidanuta.skowronski bccdc.ca
-
View Citation Hide Citation
Citation style for this article: Skowronski Danuta M, Zou Macy, Sabaiduc Suzana, Murti Michelle, Olsha Romy, Dickinson James A, Gubbay Jonathan B, Croxen Matthew A, Charest Hugues, Jassem Agatha, Krajden Mel, Bastien Nathalie, Li Yan, De Serres Gaston. Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020. Euro Surveill. 2020;25(7):pii=2000103. https://doi.org/10.2807/1560-7917.ES.2020.25.7.2000103 Received: 07 Feb 2020; Accepted: 20 Feb 2020
- Previous Article
- Table of Contents
- Next Article
Abstract
Interim results from Canada's Sentinel Practitioner Surveillance Network show that during a season characterised by early co-circulation of influenza A and B viruses, the 2019/20 influenza vaccine has provided substantial protection against medically-attended influenza illness. Adjusted VE overall was 58% (95% confidence interval (CI): 47 to 66): 44% (95% CI: 26 to 58) for A(H1N1)pdm09, 62% (95% CI: 37 to 77) for A(H3N2) and 69% (95% CI: 57 to 77) for influenza B viruses, predominantly B/Victoria lineage.
![Loading](/images/jp/spinner.gif)
Article metrics loading...
![Loading](/images/jp/spinner.gif)
![Loading full text...](/images/jp/spinner.gif)
Full text loading...
References
-
Public Health Agency of Canada (PHAC). Weekly influenza reports 2019-20 season. FluWatch report: January 26 to February 1, 2020 (Week 5). Ottawa: PHAC. [Accessed 16 Feb 2020]. Available from: https://www.canada.ca/en/public-health/services/diseases/flu-influenza/influenza-surveillance/weekly-influenza-reports.html
-
European Centre for Disease Prevention and Control (ECDC). World Health Organization (WHO) Regional office for Europe. Flu News Europe, Joint ECDC–WHO weekly influenza update, week 05/2020. [Accessed 16 Feb 2020]. Available from: http://flunewseurope.org/Archives
-
European Centre for Disease Prevention and Control (ECDC). Influenza virus characterization, December 2019. Stockholm: ECDC. [Accessed 1 Feb 2020]. Available from: https://www.ecdc.europa.eu/en/publications-data/influenza-virus-characterisation-december-2019
-
Centers for Disease Control and Prevention (CDC). FluView: Weekly influenza surveillance report. 2019-2020 influenza season week 5 ending February 1, 2020. Atlanta: CDC. [Accessed 16 Feb 2020]. Available from: https://www.cdc.gov/flu/weekly/pastreports.htm
-
World Health Organization (WHO). Influenza updates for 2019-2020 season. Geneva: WHO. [Accessed 1 Feb 2020]. Available from: https://www.who.int/influenza/surveillance_monitoring/updates/en/
-
Canadian Sentinel Practitioner Surveillance Network (SPSN). Influenza vaccine effectiveness estimates % (95% CI), 2004-05 to 2018-19 seasons. Vancouver: British Columbia Centre for Disease Control. [Accessed 1 Feb 2020]. Available from: http://www.bccdc.ca/resource-gallery/Documents/Statistics%20and%20Research/Publications/Epid/Influenza%20and%20Respiratory/SPSN_VE_By_Year_Table.pdf
-
Katz JM, Hancock K, Xu X. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther. 2011;9(6):669-683. https://doi: https://doi.org/10.1586/eri.11.51 PMID: 21692672.
-
Skowronski DM, Leir S, Sabaiduc S, Murti M, Dickinson JA, Olsha R, et al. Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019. Euro Surveill. 2019;24(4):1900055. https://doi.org/10.2807/1560-7917.ES.2019.24.4.1900055 PMID: 30696523
-
World Health Organization (WHO). WHO recommendations on the composition of influenza virus vaccines. Geneva: WHO. [Accessed 1 Feb 2020]. Available from: https://www.who.int/influenza/vaccines/virus/recommendations/en/
-
Worldwide Influenza Centre, Francis Crick Institute. September 2019 interim report. London: Francis Crick Institute. [Accessed 1 Feb 2020]. Available from: https://www.crick.ac.uk/partnerships/worldwide-influenza-centre/annual-and-interim-reports
-
Public Health Agency of Canada (PHAC). How healthy are Canadians? A trend analysis of the health of Canadians from a healthy living and chronic disease perspective. Ottawa: PHAC; 2017. [Accessed 1 Feb 2020]. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/how-healthy-canadians.html
-
Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, et al. Beyond antigenic match: possible agent-host and immuno-epidemiological influences on influenza vaccine effectiveness during the 2015-2016 season in Canada. J Infect Dis. 2017;216(12):1487-500. https://doi.org/10.1093/infdis/jix526 PMID: 29029166
-
Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, et al. Integrated sentinel surveillance linking genetic, antigenic, and epidemiologic monitoring of influenza vaccine-virus relatedness and effectiveness during the 2013-2014 influenza season. J Infect Dis. 2015;212(5):726-39. https://doi.org/10.1093/infdis/jiv177 PMID: 25784728
-
Liu STH, Behzadi MA, Sun W, Freyn AW, Liu WC, Broecker F, et al. Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance. J Clin Invest. 2018;128(11):4992-6. https://doi.org/10.1172/JCI122895 PMID: 30188868
-
Rudneva I, Ignatieva A, Timofeeva T, Shilov A, Kushch A, Masalova O, et al. Escape mutants of pandemic influenza A/H1N1 2009 virus: variations in antigenic specificity and receptor affinity of the hemagglutinin. Virus Res. 2012;166(1-2):61-7. https://doi.org/10.1016/j.virusres.2012.03.003 PMID: 22459010
-
Tsibane T, Ekiert DC, Krause JC, Martinez O, Crowe JE Jr, Wilson IA, et al. Influenza human monoclonal antibody 1F1 interacts with three major antigenic sites and residues mediating human receptor specificity in H1N1 viruses. PLoS Pathog. 2012;8(12):e1003067. https://doi.org/10.1371/journal.ppat.1003067 PMID: 23236279
-
Yasugi M, Kubota-Koketsu R, Yamashita A, Kawashita N, Du A, Misaki R, et al. Emerging antigenic variants at the antigenic site Sb in pandemic A(H1N1)2009 influenza virus in Japan detected by a human monoclonal antibody. PLoS One. 2013;8(10):e77892. https://doi.org/10.1371/journal.pone.0077892 PMID: 24147093
-
Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, et al. Vaccine effectiveness against lineage-matched and-mismatched influenza B viruses across 8 seasons in Canada, 2010-2011 to 2017-2018. Clin Infect Dis. 2019;68(10):1754-7. https://doi.org/10.1093/cid/ciy876 PMID: 30312364
-
Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, et al. Age-related differences in influenza B infection by lineage in a community-based sentinel system, 2010-2011 to 2015-2016. J Infect Dis. 2017;216(6):697-702. https://doi.org/10.1093/infdis/jix393 PMID: 28934439
-
Cowling BJ, Wu P, Lo JYC, Chan KH, Chan ELY, Fang VJ, et al. Population-based pediatric hospitalization burden of lineage-specific influenza B in Hong Kong, 2004-2014. Clin Infect Dis. 2017;65(2):300-7. https://doi.org/10.1093/cid/cix312 PMID: 28387792
-
Statistics Canada. Table 17-10-0005-01: Population estimates on July 1st, by age and sex. Ottawa: Statistics Canada. [Accessed 5 Feb 2020]. Available from: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710000501
-
Gaglani M, Vasudevan A, Raiyani C, Murthy K, Chen W, Reis M, et al. Effectiveness of trivalent and quadrivalent inactivated vaccines against influenza B in the United States, 2011-2012 to 2016-2017. Clin Infect Dis. 2020;ciaa102. https://doi.org/10.1093/cid/ciaa102 PMID: 32006430
-
Skowronski DM, Hottes TS, De Serres G, Ward BJ, Janjua NZ, Sabaiduc S, et al. Influenza Β/Victoria antigen induces strong recall of Β/Yamagata but lower Β/Victoria response in children primed with two doses of Β/Yamagata. Pediatr Infect Dis J. 2011;30(10):833-9. https://doi.org/10.1097/INF.0b013e31822db4dc PMID: 21857263
-
Skowronski DM, Hamelin ME, Janjua NZ, De Serres G, Gardy JL, Rhéaume C, et al. Cross-lineage influenza B and heterologous influenza A antibody responses in vaccinated mice: immunologic interactions and B/Yamagata dominance. PLoS One. 2012;7(6):e38929. https://doi.org/10.1371/journal.pone.0038929 PMID: 22745690
-
Skowronski DM, Sabaiduc S, Leir S, Rose C, Zou M, Murti M, et al. Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV). Euro Surveill. 2019;24(46):1900585. https://doi.org/10.2807/1560-7917.ES.2019.24.46.1900585 PMID: 31771709
-
Jorquera PA, Mishin VP, Chesnokov A, Nguyen HT, Mann B, Garten R, et al. Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011-2018. Sci Rep. 2019;9(1):2676. https://doi.org/10.1038/s41598-019-39276-1 PMID: 30804469
-
Epperson S, Davis CT, Brammer L, Abd Elal AI, Ajayi N, Barnes J, et al. Update: Influenza activity – United States and worldwide, May 19 – September 28, 2019, and composition of the 2020 southern hemisphere influenza vaccine. MMWR Morb Mortal Wkly Rep. 2019;68(40):880-4. https://doi.org/10.15585/mmwr.mm6840a3 PMID: 31600182
-
Kissling E, Pozo F, Buda S, Vilcu A-M, Gherasim A, Brytting M, et al. , I-Move Primary Care Study Team. Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15-64-year-olds in Europe: exploration by birth cohort. Euro Surveill. 2019;24(48):1900604. https://doi.org/10.2807/1560-7917.ES.2019.24.48.1900604 PMID: 31796152
-
Kelvin AA, Zambon M. Influenza imprinting in childhood and the influence on vaccine response later in life. Euro Surveill. 2019;24(48):1900720. https://doi.org/10.2807/1560-7917.ES.2019.24.48.1900720 PMID: 31796156
![Loading](/images/jp/spinner.gif)
Data & Media loading...
![](/images/commenting/icon_checkmark.png)